Literature DB >> 16650386

Serum free Fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics.

Cong-jie Wang1, Zhi-jun Zhang, Jing Sun, Xiao-bing Zhang, Xiao-dong Mou, Xiang-rong Zhang, Xiao-fang Shang, Tai-quan Zhang.   

Abstract

BACKGROUND: Weight gain and type 2 diabetes mellitus (DM) are often linked to antipsychotics treatment. The aim of the study is to investigate serum free fatty acids (FFA) levels in schizophrenic patients who received long-term antipsychotics treatment, and to explore the associations between serum FFA and fasting blood glucose, and insulin resistance.
METHODS: 308 inpatients with schizophrenia who met with the criteria of DSM-IV were recruited into this study, and were divided into four groups: control subjects, single obesity, impaired glucose tolerance (IGT) and type 2 DM according to different body mass index, fasting blood glucose level and 2-hour postprandial blood glucose. Serum FFA was measured with colorimetry. Serum insulin and leptin were measured with radioimmunoassay respectively.
RESULTS: There was a significant elevation in serum FFA levels in schizophrenic patients who received long-term antipsychotics treatment, especially in single obesity, IGT, and DM groups. The elevated serum FFA was remarkably positive correlated with fasting blood glucose and insulin resistance.
CONCLUSIONS: The study suggested the elevated serum FFA in schizophrenic patients with long-term antipsychotics treatment affected the blood glucose metabolism, may have played an important role in insulin resistance and type 2 DM, and was also an important trait of metabolic syndromes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16650386     DOI: 10.1016/j.biopsych.2006.03.014

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  15 in total

Review 1.  Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.

Authors:  Karen L Teff; Sangwon F Kim
Journal:  Physiol Behav       Date:  2011-06-12

2.  Decreased serum activity of semicarbazide-sensitive amine oxidase (SSAO) in patients treated with second generation antipsychotics: a link to impaired glucose metabolism?

Authors:  Veit Roessner; Annette Weber; Andreas Becker; Georg Beck; Helge Frieling; Stefan Bleich
Journal:  Eur J Clin Pharmacol       Date:  2007-02-28       Impact factor: 2.953

Review 3.  The effect of antipsychotic treatment on hormonal, inflammatory, and metabolic biomarkers in healthy volunteers: A systematic review and meta-analysis.

Authors:  Kyle Jon Burghardt; Wasym Mando; Berhane Seyoum; Zhengping Yi; Paul Ryen Burghardt
Journal:  Pharmacotherapy       Date:  2022-05-19       Impact factor: 6.251

Review 4.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

Review 5.  Is schizophrenia a syndrome of accelerated aging?

Authors:  Brian Kirkpatrick; Erick Messias; Philip D Harvey; Emilio Fernandez-Egea; Christopher R Bowie
Journal:  Schizophr Bull       Date:  2007-12-21       Impact factor: 9.306

6.  The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factors.

Authors:  Fabio Panariello; Gina Polsinelli; Carol Borlido; Marcellino Monda; Vincenzo De Luca
Journal:  J Obes       Date:  2012-03-07

7.  Relationship between serum levels of fetuin-A with apo-A1, apo-B100, body composition and insulin resistance in patients with type 2 diabetes.

Authors:  Farzad Shidfar; Mitra Zarrati; Mohamad Ebrahim Khamseh; Neda Haghighat; Ali Rostami; Hamid Zolfaghari
Journal:  Med J Islam Repub Iran       Date:  2014-09-20

8.  The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse.

Authors:  Andrew P Morgan; James J Crowley; Randal J Nonneman; Corey R Quackenbush; Cheryl N Miller; Allison K Ryan; Molly A Bogue; Sur Herrera Paredes; Scott Yourstone; Ian M Carroll; Thomas H Kawula; Maureen A Bower; R Balfour Sartor; Patrick F Sullivan
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

9.  Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways.

Authors:  V Mondelli; C Anacker; A C Vernon; A Cattaneo; S Natesan; M Modo; P Dazzan; S Kapur; C M Pariante
Journal:  Transl Psychiatry       Date:  2013-01-15       Impact factor: 6.222

10.  Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat.

Authors:  K J Davey; P D Cotter; O O'Sullivan; F Crispie; T G Dinan; J F Cryan; S M O'Mahony
Journal:  Transl Psychiatry       Date:  2013-10-01       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.